Biodesix CEO to discuss innovations at three November conferences
- Biodesix, Inc. announced participation in three investor conferences in New York City.
- The conferences will be held between November 19 and November 21, 2024.
- The company aims to showcase its diagnostic solutions for lung disease and engage with investors.
On October 29, 2024, Biodesix, Inc., a diagnostic solutions company specializing in lung disease, announced its participation in three upcoming investor conferences set to take place in New York City. The conferences are significant opportunities for the company to engage with investors and highlight advancements in its technologies. The scheduled events include the Craig-Hallum 15th Annual Alpha Select Conference on November 19, followed by the Wolfe Research Healthcare Conference on November 20. Finally, the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum, which will feature a presentation from Biodesix, will occur on November 21 at 1:00 PM ET. Scott Hutton, the company’s CEO, and Robin Cowie, the CFO, will represent Biodesix at these conferences. Their participation signifies a strategic move to bolster investor relations and communicate the company's mission and innovations effectively. These investor meetings offer a platform for engaging potential investors and discussing the company's growth trajectory. Biodesix is known for its blood-based Nodify Lung® Nodule Risk Assessment tests, which aid physicians in assessing the risk of malignancy in pulmonary nodules. Such diagnostic solutions position Biodesix as a key player in the healthcare sector, particularly in lung disease management, enhancing their visibility in the investment community.